Clinical trials
Recurrent Cancer clinical trials
Below are recruiting recurrent cancer clinical trials, each written for real people, not researchers. We’re tracking 688 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06404983Recruiting
Opioid-free anesthesia for breast cancer surgery
This study tests whether breast cancer surgery can be done safely without using opioid pain medicines during anesthesia. The goal is to see if avoiding opioids leads to fewer side effects and a smoother recovery.
Ioannina, EpirusAges 18–99 - NCT06958926Recruiting
Study of colon cancer that returns after surgery
This study looks at colon cancer that comes back in the same area after surgery. It may help doctors understand how to better treat this type of recurrence.
HsinchuAges 18 years+ - NCT07256236RecruitingPhase 2
SKB264 plus QL1706 for advanced cervical cancer
This trial tests a combination of two drugs—SKB264 and QL1706—for women with cervical cancer that has come back or spread and is not curable with standard treatments. The goal is to see if this new combination can help shrink tumors or slow the disease.
Fuzhou, FujianAges 18 years+ - NCT06678724Recruiting
Blood test study for head and neck cancer that has returned or spread
This trial is testing a new blood test (called a liquid biopsy) to better understand and predict the course of head and neck cancers that have come back or spread. If you join, researchers will use a special chip to look at your immune cells and tumor cells in your blood.
Zhubei, HsinChu CountyAges 20 years+ - NCT05444478Recruiting
Microwave ablation plus lenvatinib for recurrent liver cancer
This trial tests whether combining heat treatment to kill liver tumors (microwave ablation) with the medicine lenvatinib can better control recurrent hepatocellular carcinoma (HCC). It may help shrink tumors or slow growth for people whose cancer has come back but who have limited tumor burden.
Changsha, HunanAges 18–75 - NCT05710848RecruitingPhase 1/Phase 2
Study drug for repeat bladder tumor surgery patients
This trial tests STM-416, given around the time you have surgery to remove recurring bladder tumors, to see if it can reduce the chance the cancer comes back. It is for people with high-risk early bladder cancer (non–muscle-invasive) who have already had standard treatment and now need another TURBT.
Mesa, ArizonaAges 18 years+ - NCT07213934RecruitingPhase 1/Phase 2
Immunotherapy and radiation before surgery for recurrent head and neck cancer
This trial tests a new combination for people whose head and neck cancer has come back after prior radiation. You'll receive an immunotherapy drug (pembrolizumab) plus radiation, then surgery. The goal is to see if this approach can improve how well surgery works.
Cincinnati, OhioAges 18 years+ - NCT05559879RecruitingPhase 1/Phase 2
Cabozantinib and dostarlimab for recurrent gynecologic carcinosarcoma
This trial tests the combination of cabozantinib and dostarlimab to treat recurrent (coming back) gynecologic carcinosarcoma, after standard chemotherapy has already been tried. It aims to shrink tumors and improve outcomes by targeting cancer pathways.
Birmingham, AlabamaAges 18 years+ - NCT05595590RecruitingPhase 2
Radiation plus immunotherapy for recurrent head and neck cancer
This study tests whether adding an immunotherapy medicine called tislelizumab to radiation can better control recurrent (coming back) head and neck squamous cell cancer. It is aimed at people whose cancer can’t be fully removed by surgery or can’t be safely removed.
Chengdu, SichuanAges 18–75 - NCT06184035RecruitingPhase 1/Phase 2
Testing a radioactive drug for advanced solid tumors
This trial tests a new radioactive drug, 177Lu-SN201, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors and to find the best dose.
Adelaide, South AustraliaAges 18 years+ - NCT04858880Recruiting
Personalized radiation for PSA rise after prostate surgery
This study tests a tailored (personalized) radiation plan for men whose PSA (“prostate blood test”) rises after prostate surgery but who have no detectable spread on scans. It may help control cancer growth by targeting the right area based on your situation.
JönköpingAges 18 years+ - NCT05104736RecruitingPhase 2
PT-112 for thymus gland tumors after prior chemotherapy
This trial studies PT-112, a new treatment, in people with thymoma or thymic carcinoma that has grown despite at least one prior platinum chemotherapy treatment. It may help shrink tumors or slow disease progression, especially when surgery is not possible.
Bethesda, MarylandAges 18–120 - NCT06040970RecruitingPhase 1/Phase 2
Sacituzumab govitecan plus cisplatin for recurrent ovarian/endometrial cancer
This trial tests a combination of two drugs—sacituzumab govitecan and cisplatin—for women with ovarian or endometrial cancer that has come back after responding to platinum chemotherapy. The goal is to see if the combination works better than current options.
New York, New YorkAges 18 years+ - NCT07631572Recruiting
Cesium implant radiation for recurrent cervical or uterine cancer
This study tests a type of internal radiation (cesium implant) to treat cancer that has come back in the vagina after previous pelvic radiation. The goal is to save the organ while treating the cancer.
Lexington, KentuckyAges 18 years+ - NCT05838521RecruitingPhase 2
IMMU-132 for cervical cancer that returned or did not go away
This trial studies IMMU-132 (sacituzumab govitecan) in people whose cervical cancer keeps coming back or stays after prior treatment. It aims to shrink tumors and improve outcomes after at least one chemotherapy has already been tried.
New Haven, ConnecticutAges 18 years+ - NCT06952660RecruitingPhase 4
Eye tests for people taking Tivdak for cervical cancer
This trial is for people with cervical cancer that has come back or spread and is getting worse after chemotherapy. It will check your eyes regularly while you take Tivdak to see how the drug affects them.
Phoenix, ArizonaAges 18 years+ - NCT04486352RecruitingPhase 1/Phase 2
Targeted therapy trial for recurrent or persistent endometrial cancer
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
Duarte, CaliforniaAges 18 years+ - NCT05684731RecruitingPhase 1
Test drug KM1 for repeat or resistant ovarian cancer
This early-phase study tests whether KM1 is safe and can shrink or control ovarian, fallopian tube, or primary peritoneal cancer that has come back or not responded to standard treatment. It may help people who have limited options, but eligibility is strict to keep participants safe.
Wuhan, HubeiAges 18 years+ - NCT05932212RecruitingPhase 2
Study drug for vulvar cancer after prior treatment failure
This Phase 2 trial tests AK104 in people with recurrent or metastatic vulvar cancer that cannot be cured with surgery or strong radiation. It may help shrink tumors or slow growth, especially if you’ve already tried standard treatments or couldn’t tolerate them.
Fuzhou, FujianAges 18–80 - NCT06155396RecruitingPhase 2
Targeted drug combo for advanced cervical cancer
This trial tests a combination of two drugs: an antibody-drug conjugate (RC48-ADC) that targets HER2 on cancer cells, plus an immunotherapy (Zimberelimab) that helps your immune system attack the cancer. It is for people with advanced cervical cancer whose prior platinum-based chemotherapy has stopped working.
Bengbu, AnhuiAges 18 years+ - NCT06185569Recruiting
French study on outcomes in HR+/HER2- early breast cancer patients with Oncotype DX
This study looks at how well treatments work for people with early-stage, hormone receptor-positive, HER2-negative breast cancer when the Oncotype DX test helps guide therapy. It aims to understand real-world outcomes in French patients.
BesançonAges 18 years+ - NCT06459687RecruitingPhase 3
Socazolimab for first-line treatment of advanced cervical cancer
This phase 3 trial tests a new immunotherapy drug called socazolimab combined with chemotherapy as a first treatment for cervical cancer that has come back, spread, or cannot be removed with surgery or radiation. The goal is to see if it helps shrink tumors and improves survival.
Hefei, AnhuiAges 18–75 - NCT06518564RecruitingPhase 2
Avelumab and M1774 for ARID1A-mutated endometrial cancer
This trial tests a combination of two drugs, avelumab (an immunotherapy) and M1774, in people with a specific type of endometrial cancer that has an ARID1A gene mutation. The goal is to see if this combination can shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT06692166RecruitingPhase 3
New drug vs standard chemo for advanced cervical cancer
This trial tests a new drug called 9MW2821 against standard chemotherapy options for cervical cancer that has come back or spread. The goal is to see if the new drug works better than the usual treatments, and you must have already tried a platinum-based chemotherapy.
BeijingAges 18–75
Hear when a new Recurrent Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent cancer?
- Yes. Clin2 currently lists 688 recruiting recurrent cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.